Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14003866 | 1.00 | GCK (0.66) | GCKKCNH2 | |
| SCHEMBL14349638 | 0.94 | GCK (0.66) | GCKKCNH2 | |
| SCHEMBL2656411 | 0.94 | GCK (0.66) | GCKKCNH2 | |
| SCHEMBL14349636 | 0.93 | GCK (0.64) | GCKKCNH2 | |
| SCHEMBL5622118 | 0.93 | GCK (0.64) | GCKKCNH2 | |
| SCHEMBL14003865 | 0.91 | GCK (0.66) | GCKKCNH2 | |
| SCHEMBL4887186 | 0.91 | GCK (0.66) | GCKKCNH2 | |
| SCHEMBL1146985 | 0.91 | GCK (0.80) | GCKKCNH2 | |
| SCHEMBL13891547 | 0.91 | GCK (0.80) | GCKKCNH2 | |
| SCHEMBL1146986 | 0.90 | GCK (0.63) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280874-A1 | Phenoxy Benzamide Compounds with Utility in the Treatment of Type 2 Diabetes and Obesity | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | claimed |
| EP-1856056-A1 | PHENOXY BENZAMIDE COMPOUNDS WITH UTILITY IN THE TREATMENT OF TYPE 2 DIABETES AND OBESITY | AstraZeneca AB (SE) | 2007-11-21 | — | — | EP | claimed |
| WO-2006040528-A1 | PHENOXY BENZAMIDE COMPOUNDS WITH UTILITY IN THE TREATMENT OF TYPE 2 DIABETES AND OBESITY | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | claimed |
| US-20080280874-A1 | Phenoxy Benzamide Compounds with Utility in the Treatment of Type 2 Diabetes and Obesity | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280874-A1 | Phenoxy Benzamide Compounds with Utility in the Treatment of Type 2 Diabetes and Obesity | GRK4, PTGER4, GPR119 | GCK 30/4885KCNH2 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.